Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-08-2016 | Editorial Commentary

Is ¹⁸FDG uptake useful to decide on chemotherapy in ER+/HER2- breast cancer?

Authors: David Groheux, Elif Hindié

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 9/2016

Excerpt

Dear Sir, …

NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Version 1. 2016. Available at:http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.

Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869–74.CrossRefPubMedPubMedCentral

Groheux D, Hatt M, Hindié E, Giacchetti S, de Cremoux P, Lehmann-Che J, et al. Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18) F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy. Cancer. 2013;119:1960–8.CrossRefPubMed

Harris LN, Ismaila N, McShane LM, Andre F, Collyar DE, Gonzalez-Angulo AM, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2016;34:1134–50.CrossRefPubMed

Groheux D, Giacchetti S, Moretti J-L, Porcher R, Espié M, Lehmann-Che J, et al. Correlation of high (18)F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2011;38:426–35.CrossRefPubMed

Groheux D, Majdoub M, Tixier F, Le Rest CC, Martineau A, Merlet P, et al. Do clinical, histological or immunohistochemical primary tumour characteristics translate into different (18)F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer? Eur J Nucl Med Mol Imaging. 2015;42:1682–91.CrossRefPubMed

Lee SH, Ha S, An HJ, Lee JS, Han W, Im SA et al. Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancers. Eur J Nucl Med Mol Imag. 2016.

Ahn SG, Lee M, Jeon TJ, Han K, Lee HM, Lee SA. [18F]-Fluorodeoxyglucose positron emission tomography can contribute to discriminate patients with poor prognosis in hormone receptor-positive breast cancer. PLoS ONE. 2014;9:e105905.CrossRefPubMedPubMedCentral

Ahn SG, Lee JH, Park JT, Lee HM, Jeon TJ, Ryu YH et al. Standardize uptake value of 18F-FDGPET- CT is in accordance with the 21-gene recurrence score (Oncotype DX) in ER-positive and HER2- negative breast cancer patients. IMPAKT Breast Cancer Conference; May; Brussels, Belgium: Oxford University Press on behalf of the European Society for Medical Oncology. 2015. p. 73.

10.

Aogi K, Kadoya T, Sugawara Y, Kiyoto S, Shigematsu H, Masumoto N, et al. Utility of (18)F FDG-PET/CT for predicting prognosis of luminal-type breast cancer. Breast Cancer Res Treat. 2015;150:209–17.CrossRefPubMedPubMedCentral

11.

Groheux D, Cochet A, Humbert O, Alberini J-L, Hindié E, Mankoff D. 18F-FDG PET/CT for staging and restaging of breast cancer. J Nucl Med. 2016;57 Suppl 1:17S–26.CrossRefPubMed

12.

Segaert I, Mottaghy F, Ceyssens S, De Wever W, Stroobants S, Van Ongeval C, et al. Additional value of PET-CT in staging of clinical stage IIB and III breast cancer. Breast J. 2010;16:617–24.CrossRefPubMed

13.

Groheux D, Hindié E, Delord M, Giacchetti S, Hamy A-S, de Bazelaire C, et al. Prognostic impact of 18FDG-PET-CT findings in clinical stage III and IIB breast cancer. J Natl Cancer Inst. 2012;104:1879–87.CrossRefPubMedPubMedCentral

14.

Groheux D, Espié M, Giacchetti S, Hindié E. Performance of FDG PET/CT in the clinical management of breast cancer. Radiology. 2013;266:388–405.CrossRefPubMed

15.

Groheux D, Giacchetti S, Delord M, Hindié E, Vercellino L, Cuvier C, et al. 18F-FDG PET/CT in staging patients with locally advanced or inflammatory breast cancer: comparison to conventional staging. J Nucl Med. 2013;54:5–11.CrossRefPubMed

16.

Humbert O, Berriolo-Riedinger A, Cochet A, Gauthier M, Charon-Barra C, Guiu S, et al. Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using (18)F-FDG PET in luminal HER2-negative breast cancer. Eur J Nucl Med Mol Imaging. 2014;41:416–27.CrossRefPubMed

17.

García Vicente AM, Soriano Castrejón Á, López-Fidalgo JF, Amo-Salas M, Muñoz Sanchez MDM, Álvarez Cabellos R, et al. Basal (18) F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography as a prognostic biomarker in patients with locally advanced breast cancer. Eur J Nucl Med Mol Imaging. 2015;42:1804–13.CrossRefPubMed

18.

Groheux D, Sanna A, Majdoub M, de Cremoux P, Giacchetti S, Teixeira L, et al. Baseline tumor 18F-FDG uptake and modifications after 2 cycles of neoadjuvant chemotherapy are prognostic of outcome in ER+/HER2- breast cancer. J Nucl Med. 2015;56:824–31.CrossRefPubMed

19.

van Kruchten M, de Vries EGE, Brown M, de Vries EFJ, Glaudemans AWJM, Dierckx RAJO, et al. PET imaging of oestrogen receptors in patients with breast cancer. Lancet Oncol. 2013;14:e465–75.CrossRefPubMed

Title: Is 18FDG uptake useful to decide on chemotherapy in ER+/HER2- breast cancer?
Authors: David Groheux
Elif Hindié
Publication date: 01-08-2016
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 9/2016
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-016-3430-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Is ¹⁸FDG uptake useful to decide on chemotherapy in ER+/HER2- breast cancer?

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 9/2016

Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm

Andreas Engert and Anas Younes (Eds), Hodgkin Lymphoma: A Comprehensive Overview

[11C]TASP457, a novel PET ligand for histamine H3 receptors in human brain

In vivo PET imaging of the neuroinflammatory response in rat spinal cord injury using the TSPO tracer [18F]GE-180 and effect of docosahexaenoic acid

Tau PET and tauopathies

William T. O’Brien Sr. (Ed.), Top 3 Differentials in Neuroradiology: A Case Review. Thieme Medical Publishers, Inc., 2015. ISBN 978-1- 60406-723-1